Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

NCT05350774 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

45

Enrollment

NIH

Sponsor class

Conditions

Systemic Inflammation
Neuroinflammation
Microvascular Thrombosis

Interventions

DRUG: IV normal saline
DRUG: IV immunoglobulin

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)